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Midostaurin (PKC412A), N-benzoyl-staurosporine, potently inhibits protein kinase C alpha (PKCa), VEGFR2, KIT, PDGFR and FLT3
tyrosine kinases. In mice, midostaurin slows growth and delays lung metastasis of melanoma cell lines. We aimed to test midostaurin’s
safety, efficacy and biologic activity in a Phase IIA clinical trial in patients with metastatic melanoma. Seventeen patients with advanced
metastatic melanoma received midostaurin 75mg p.o. t.i.d., unless toxicity or disease progression supervened. Patient safety was
assessed weekly, and tumour response was assessed clinically or by CT. Tumour biopsies and plasma samples obtained at entry and
after 4 weeks were analysed for midostaurin concentration, PKC activity and multidrug resistance. No tumour responses were seen.
Two (12%) patients had stable disease for 50 and 85 days, with minor response in one. The median overall survival was 43 days.
Seven (41%) discontinued treatment with potential toxicity, including nausea, vomiting, diarrhoea and/or fatigue. One patient had
450% reduction in PKC activity. Tumour biopsies showed two PKC isoforms relatively insensitive to midostaurin, out of three
patients tested. No modulation of multidrug resistance was demonstrated. At this dose schedule, midostaurin did not show clinical or
biologic activity against metastatic melanoma. This negative trial reinforces the importance of correlating biologic and clinical
responses in early clinical trials of targeted therapies.
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Midostaurin (PKC412A, CGP41251), N-benzoyl-staurosporine, is a
potent inhibitor of calcium- or diacylglycerol-dependent isoforms
of protein kinase C (PKCa, PKCbI, PKCbII and PKCg), and VEGF-
R2, PDGFR, KIT and Flt-3 kinases (Fabbro et al, 2000; Weisberg
et al, 2002). Although midostaurin is a competitive inhibitor of
ATP binding to PKCa, midostaurin is most active in inhibiting
particulate (active) PKC enzymes from tumour samples (Killion
et al, 1995; Ikegami et al, 1996).
In vitro, midostaurin slows tumour cell growth, in G2/M phase,
inducing polyploidy, apoptosis and radiosensitivity, with inhibi-
tion of the PI3K/Akt pathway (Fabbro et al, 2000; Tenzer et al,
2001). In vivo midostaurin inhibits growth of several murine
tumours, potentiates paclitaxel, doxorubicin and radiation, and
may affect multidrug resistance (Utz et al, 1994; Fabbro et al,
2000). Angiogenesis is also inhibited by midostaurin (Ozaki et al,
2000).
The incurability of metastatic melanoma indicates a need for
new therapy, preferably targeted against molecular changes
associated with tumorigenicity (Brown and Kirkwood, 2003).
Protein kinase C alpha activity is elevated in some melanoma cells
and is a potential target (Selzer et al, 2002). Midostaurin inhibits
PKCa activity in melanoma cells, and delays their lung metastasis
in mice (Yoshikawa et al, 2003). So, midostaurin might be useful
clinically in patients with metastatic melanoma.
In a Phase I trial, 32 patients with advanced cancer received oral
midostaurin at 12.5–300mgday
 1 (Propper et al, 2001). Between
two patients with cholangiocarcinoma, one had stable disease and
one a partial response for 4 months on midostaurin. No other
responses were seen. Frequent but mild toxicities were nausea,
vomiting, fatigue and diarrhoea. MTD was not reached, but at
225–300mgday
 1, 15 out of 16 patients had nausea/vomiting
(grade 3 in 3); and six out of 16 had grade 2 diarrhoea. There was
minimal myelosuppression.
Midostaurin dose and AUC (0–24h) showed linear correlation,
but with marked inter-patient variability. Estimated median
elimination t1/2 was 1.6 days (range: 0.9–4.0 days). Several active
metabolites, including one (CGP52421 e2) with a median t1/2 of 36
days, were also detected (Figure 1).
The objectives of this Phase IIa trial of midostaurin in patients
with advanced metastatic melanoma were to evaluate mido-
staurin’s effects on measurable disease, to further define its
toxicity, and to investigate drug concentrations and biological
activity in tumour biopsies and plasma.
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sPATIENTS AND METHODS
Eligibility
Patients with stage IV metastatic melanoma that had progressed
despite any previous therapy were eligible if they were 18 years of
age or older, had an ECOG performance status of 0–2, had
adequate haematologic, renal and hepatic function, had bidimen-
sionally measurable disease, and were able to provide informed
consent. There was no limit on the amount of prior therapy, but no
prior chemotherapy or immunotherapy was permitted in the 4
weeks before study entry. Patients with CNS metastases were
eligible. At least the first 14 patients entered were also required to
have at least two lesions suitable for excision biopsy (skin,
subcutaneous metastases). Written informed consent was obtained
from all patients and the protocol was approved by the Human
Research Ethics Committees of the participating institutions.
Treatment
All patients were treated with midostaurin 75mg (6% ww
 1 in
Gelucire 44 out of 14) given orally three times a day (225mgday
 1)
continuously until disease progression or unacceptable toxicity.
This fixed dose schedule was calculated from the Phase I study, in
which higher single daily doses were associated with more GIT
toxicity. However, if grade 3 toxicity considered related to
midostaurin occurred, treatment was withheld for up to 7 days
then continued at 75mg twice daily (150mgday
 1). Patients were
instructed to take midostaurin with food while sitting upright, to
reduce nausea.
Patients were reviewed for safety and efficacy of midostaurin
weekly for the first month, and then on a monthly basis, or more
frequently where symptoms warranted. Disease sites were re-
evaluated by clinical examination monthly or CT every 2 months,
or more frequently if disease progression was suspected.
Assays for biologic activity
To determine any biologic activity of midostaurin, patients had
tumour biopsies and plasma taken for analyses in the week prior to
starting midostaurin and again, where practical, on day 28.
Tumour biopsies were immediately frozen in liquid nitrogen and
stored at  701C until analysis. Heparinised blood (10ml) was
collected predose and at day 28. Following centrifugation, plasma
was stored at  701C until assay for MDR-reversing ability, and for
concentrations of midostaurin and its two main metabolites
CGP62221 and CGP52421 e2 (Figure 1).
Preparation of cytosolic and particulate fractions from tumour
biopsies Tumours were powdered in liquid nitrogen and homo-
genised on ice using an Ultra-Turrax in a buffer containing 20mM
HEPES, pH 7.4, 2mM EDTA, 25mM b-glycerophosphate, 0.2mM
DTT, 10mgml
 1 leupeptin, 10mgml
 1 aprotinin, 1mgml
 1 pep-
statin, 1mM sodium orthovanadate and 0.5mM PMSF. Extracts
were then sonicated in an ice cold sonicating bath for 5min before
centrifugation at 1000g for 5min to remove cellular debris.
Supernatants were centrifuged at 50000g for 15min to separate
cytosolic (supernatant) and particulate (pellet) fractions. The
supernatant was kept as ‘cytosolic’ fraction. The pellet was further
extracted by resuspension in the original lysis buffer including 1%
O
N
H
N N
H
O
N
O
O
O
N
H
N N
H H3C H3C H3C
H3C
H3C
H3C H3C
H3C H3C H3C
H3C H3C H3C
N
O
O
H3C O
HO
O
N
H
N N
H
HO
N
O
O
MIDOST CGP 62221 CGP 52421 
e1, e2 
O
N N
H
N
O
O
H3C O
O
N
H
N
H
N
H
N N
H
H3C O
N
O
O
HO
O
N N
H
HO
N
O
O
MIDOST CGP 62221 CGP 52421 
e1, e2 
Figure 1 Chemical structures of MIDOSTAURIN and its O-desmethyl metabolite CGP62221 (O-D-MIDOSTAURIN) and 7-hydroxy metabolite
CGP52421 (7-OH-MIDOSTAURIN), the later has two epimers, e1 and e2.
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sNP-40. Following sonication for 5min on ice, the extract was
centrifuged at 50000g for 15min. The supernatant from this spin
(which derived from the original pellet) was kept as the
‘particulate’ fraction. All steps were performed at 41C or on ice.
Protein measurement The protein concentrations of the cytosolic
and particulate fractions were measured after TCA precipitation
using the Dc protein assay kit (Bio-Rad).
PKC activity measurements Intratumoral total PKC activity was
measured in cytosolic and particulate fractions using protamine
sulphate as the substrate, following the method of a validated assay
(Budworth and Gescher, 1995). The PKC assay was performed with
4–5ml of the cytosol or particulate extract (2–50mg protein) in a
total reaction volume of 200ml, including 200mgml
 1 protamine
sulphate, 150mM (g-
32P)ATP (200c.p.m.pmol
 1) in a buffer
containing 20mM Tris-HCl, pH 7.4, 10mM magnesium acetate
and 0.5mM EGTA. The reaction was terminated after 6–7min
(301C) by spotting 35ml of the mix onto P81 phosphocellulose
paper, followed by washing in 75mM phosphoric acid. Bound,
phosphorylated protamine sulphate was quantitated by scintilla-
tion counting of the phosphocellulose papers. Protein kinase C
activity was determined by phosphate incorporation into prota-
mine sulphate and expressed as picomolar of phosphate trans-
ferredminmg
 1 protein. Measurements were performed in
triplicate. Each patient’s pretreatment and day 28 biopsies were
processed together and analysed in the same assay run. Up to six
patients’ samples could be analysed in one day to minimise
interassay variability. Initial experiments on melanoma biopsies
from nontrial patients showed addition of 10mM midostaurin to
melanoma biopsies inhibited phosphorylation.
Western blotting for PKC isoform abundance For three patients,
2mg of cytosol and particulate proteins from baseline and day 28
biopsies were resolved on 15% acrylamide SDS-PAGE gels,
transferred onto PVDF membrane and probed with antibodies to
PKC isoforms (Santa Cruz).
Drug concentrations in plasma and tumour tissue Plasma
concentrations of midostaurin and its two main metabolites CGP
62221 and CGP52421 e2 were determined using an HPLC method
with fluorescence detection as reported previously (Van Gijn et al,
1995; Propper et al, 2001). Homogenisation of the tumour tissue by
freeze-fractionating proved impossible. Therefore, the tumour
tissue was frozen and cut into as small as possible pieces with a
scalpel. The pieces were weighed, added to 1ml of water, vortexed
and thereafter treated like plasma. The assay for plasma samples
was validated with acceptable calibration curves, within-study
variability and total recovery. The limit of quantitation (LOQ) in
these analyses (defined as the concentration of the lowest QC
sample with a mean recovery of 80–120% and a CV p20%) was
36nmoll
 1 for MIDOSTAURIN, 61nmoll
 1 for CGP 62221, and
265nmoll
 1 for CGP52421 e2. Due to limited availability of
tumour tissue, the within-study validation for tumour assay was
not performed. The tissue assay showed good recovery for
PKC412, 95.876.2%, and for CGP62221, 103.2713.0%. The LOQ
in tissue homogenate was 48nmoll
 1 for midostaurin, 82nmoll
 1
for CGP 62221, and 357nmoll
 1 for CGP52421 e2.
Potential modulation of multidrug resistance This was deter-
mined using a previously reported method that assessed the
capacity of cremophor EL to inhibit MDR
10. Briefly, the ability of
the patient’s plasma to modulate ex vivo intracellular daunorubicin
accumulation in multidrug resistant cells (R100; CCRF CEM cells
resistant to 100ngml
 1 vinblastine) was measured using fluores-
cence detection. The activity of 20mgml
 1 Valspodar (PSC833, an
inhibitor of P-glycoprotein) added to the patient’s prestudy plasma
sample defined 100% reversal (no accumulation of daunorubicin).
In addition, 20mgml
 1 midostaurin was added to a prestudy
sample for estimation of potential activity, and as an inter-patient
control. The modulating ability of day 29 plasma samples was
determined relative to this. All assays were performed in triplicate.
Blank plasma was spiked with 1.0mlml
 1 cremophor EL and run as
an inter-assay control. This concentration of cremophor EL caused
approximately 50% inhibition of maximum daunorubicin accu-
mulation (Webster et al, 1993). The accuracy of the control was
always 475%.
Sample size
It was planned to recruit 14 patients with disease suitable for
biopsy as the first cohort. If no responses were seen, the trial would
close. If at least one response occurred, a further 13 patients (not
necessarily with disease suited for biopsy) would be recruited.
Response and toxicity were assessed using WHO criteria.
RESULTS
Patient demographics and prior therapies
Seventeen patients with progressive metastatic melanoma were
enrolled in the study (Table 1). All were Caucasian, aged 26–77
Table 1 Patient demographics and tumour responses
Patient Age/sex Prior therapy Days on midostaurin Best response (duration)
1 52M Chemotherapy 60 PD
2 51M Chemotherapy, tamoxifen 15 PD
3 34M Chemotherapy 58 PD
4 45F Chemotherapy 16 PD
5 57F Chemotherapy, tamoxifen, radiation therapy 57 SD (50 days)
6 60F Chemotherapy, radiation therapy 8 PD
7 52M Radiation therapy 23 PD
8 68M Chemotherapy, radiation therapy 33 PD
9 54M Chemotherapy, tamoxifen, radiation therapy 37 PD
10 53M Radiation therapy 64 PD
11 63M Chemotherapy 56 PD
12 74M None 113 SD (85 days)
13 55M Chemotherapy, tamoxifen 25 NA
14 59M Chemotherapy 57 PD
15 77F Tamoxifen 27 PD
16 26M Chemotherapy 15 PD
17 56F Tamoxifen, radiation therapy 57 PD
PD, progressive disease; SD, stable disease (o25% increase overall diameter of any lesion; no new lesions, after at least 4 weeks); NA, not assessable.
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s(median: 55) years, with 12 males and 5 females. Patients’ median
ECOG performance status was 1 at study entry. Twelve had
received chemotherapy (most commonly with dacarbazine,
cisplatin or carmustine). Six had received immunotherapy: five
with a-interferon and four with interleukin 2. Seven had also
received radiation therapy and six had received tamoxifen.
Efficacy and safety
No patient obtained a tumour response on midostaurin therapy.
Two out of 17 (12%) had stable disease for 50 and 85 days
respectively until tumour progression. In one patient (number 12
in Table 1) – the only patient who had not been pretreated for
metastatic melanoma – a brief minor tumour response was seen.
Fourteen out of 17 (82%) had progressive disease, and one patient
was not assessable for response. All patients have died. The median
survival was 43 days (range: 8–113 days).
No patient’s ECOG performance status improved while on study.
Eight (47%) had no change, and nine (53%) patients had
worsening of their performance status.
Ten patients discontinued the study due to unsatisfactory
therapeutic effect and 7 (41%) patients discontinued from the
study owing to nausea, vomiting, diarrhoea and/or fatigue,
possibly related to the study drug, in association with lack of
therapeutic response. two out of 17 patients died on study,
although their deaths were not thought to be related to
midostaurin therapy. Two patients required dose modification of
midostaurin for nausea or vomiting.
Elevated liver enzymes (alanine transaminase or aspartate
transaminase) possibly linked to therapy were recorded in four
patients but only one reached grade 2 severity. Four patients had
hyperglycemia, one of Grade 2 severity. Anaemia occurred in 12
patients, in five of whom it reached grade 2.
Biologic activity of midostaurin
All 17 patients had baseline tumour biopsies and plasma samples
taken for biologic assays at baseline. Nine patients had repeat
biopsies and 12 repeat plasma samples, with the remaining
patients discontinuing the study early.
Results of PKC assay on tumour biopsies are shown in Figure 2.
Compared to the pretreatment biopsy, cytosolic PKC activity was
reduced by 7–91% in seven out of nine patients. Particulate PKC
activity was reduced by 11% to 79% in four out of nine patients.
Only one patient (Patient 10) had 450% inhibition in both
fractions; however, this patient had progressive disease. On day 0,
the percentage of the total PKC activity present in the particulate
fraction ranged from 12 to 37% and on day 28 it ranged from 11 to
35%. The percentage of the total PKC activity present in the
particulate fraction fell from day 0 to day 28 in two out of nine
patients – in patient 10 from 19.1 to 15.4% and in patient 11 from
15.7 to 11.1%.
Varying patterns of PKC isoforms were seen in three patients
(Figure 3) Protein kinase C alpha was predominant in two patients.
However, one of these patients, who was resistant to midostaurin
(unchanged cytosolic activity and 65% increase in particulate
activity), showed an abundance of PKCx, an isoform refractory to
inhibition by midostaurin (IC5041000mM). The third patient
(patient 12) had predominance of PKCd, which is only moderately
sensitive to midostaurin (IC50 0.36mM). This patient had stable
disease for 85 days.
Modulation of multidrug resistance and tissue/plasma
distribution
Addition of 20mgml
 1 midostaurin to pretreatment plasma
produced 14–64% (mean 40%) of potential maximal reversal of
multidrug resistance. However, plasma from patients receiving
midostaurin showed o20% potential maximum reversal in all 12
patients, and in 10 out of 12 patients it was o10%.
Plasma and tumour concentrations of midostaurin and
metabolites
Concentrations of midostaurin and its two metabolites CGP62221
and CGP52421 e2 in plasma and tumour after approximately 1
month 75mg tid doses are shown in Table 2. In plasma,
midostaurin trough concentrations ranged between 771 to
4649nM (median 2342nM), and it was B2-fold lower than
CGP62221 (median 5433nM) and B7-fold lower than CGP52421
(18429nM). In tumour tissue, the concentration differences
between midostaurin and its metabolites were less pronounced.
Midostaurin tissue concentration 593nM (median) was comparable
to CGP62221 (710nM), and only B2-fold lower than CGP52421
(1516nM). The tissue to plasma concentration ratio was similarly
low between midostaurin and CGP62221, 0.29 and 0.20, respec-
tively, and the ratio for CGP52421 was the lowest, 0.083.
DISCUSSION
In this phase IIA clinical trial, no activity of midostaurin at the
75mg tid dosing regimen was observed, and toxicity led to early
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Figure 2 PKC activity in patients’ melanoma biopsies before and during
midostaurin therapy.
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Figure 3 Western blots of PKC isoforms in melanoma biopsies from
three patients before and during midostaurin therapy (left to right, patient
number 8, 9, 12). Cyt¼cytosolic, Part¼particulate, PKC Act¼PKC
activity on corresponding day.
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sdiscontinuation in seven out of 17 (41%) patients with metastatic
melanoma. Most patients had received prior chemotherapy, had
large metastases amenable to biopsy, and had short life
expectancy. However, these results are similar to the negative
results of Phase II trial in melanoma with ISIS3521 (an antisense
oligonucleotide against PKCa) in which no responses were seen in
23 chemo-naı ¨ve patients (Fumoleau et al, 2000).
Grade 3 toxicity was infrequent, but a constellation of less severe
symptoms including nausea, vomiting, diarrhoea and fatigue,
contributed to the decision to discontinue midostaurin in seven
out of 17 (41%) patients. After the start of this trial, the final report
of a Phase I study (Propper et al, 2001) suggested 75mg bid
(150mgday
 1) as more tolerable midostaurin dosing for long-
term administration. However, a recent Phase II trial of
midostaurin to inhibit activated Flt3 kinase in acute myeloid
leukaemia (AML) found 225mgday
 1 well-tolerated and had
promising activity (Stone et al, 2005).
A major component of this trial was procurement of tumour and
plasma samples for evaluation of target inhibition and pharma-
codynamic efficacy. Because many patients had disease progres-
sion and deteriorating performance status at the first assessment,
only nine of the 17 patients were able to have a repeat biopsy
performed after 4 weeks of midostaurin treatment. The results of
the assay for inhibition of PKC activity were interesting. Despite
midostaurin’s potency as an inhibitor of the major isoforms of
PKC (IC50 22nM for PKCa) (Fabbro et al, 2000), it has been a
challenge to increase free concentration to an optimal level because
of its high plasma protein binding (99%, Novartis internal report).
For a plasma concentration of 2342nM (median), the free
concentration will be only 23.4nM, which is in the same range as
the IC50 against PKCa. Although the two metabolites CGP62221
and CGP52421 are also active against PKC isotypes, their in vivo
activity is probably limited. CGP62221 has a weaker activity (IC50
120nM) than that of the parent drug. CGP52421 has a similar
activity (IC50 50nM) as the parent drug and a higher plasma
concentration, but its substantially high plasma protein binding
(b99%, Novartis internal report) renders it less active in vivo than
the parent drug. Thus, considering the large inter-patient
variability for midostaurin plasma concentration and the marginal
free concentration relative to the IC50 value, it was not surprising
that the results showed an inconsistent and variable inhibition of
PKC activity in melanoma deposits in vivo.
In a small sample of three patients’ tumours, two out of three
expressed PKC isoforms known to be insensitive to inhibition by
midostaurin. However, larger studies on PKC isoforms in human
tumours are needed to determine the significance of this finding.
Solid tumours such as melanoma may also be poorly perfused and
hypoxic, so that low penetration of midostaurin (tissue/plasma
ratio median 0.29) into solid tumours may also account for
inconsistent intra-tumoral PKC inhibition.
Our results are in contrast to those obtained with midostaurin in
AML where inhibition of autophosphorylation of mutated Flt-3
was documented in leukaemic blasts isolated from patients
receiving midostaurin (Stone et al, 2005). In 70% of AML patients,
there was a 50% reduction of peripheral blood blast cells, and in
25% of patients a 50% reduction in bone marrow blast cells.
Because midostaurin had been reported to modulate multidrug
resistance, we determined this potential in patients’ plasma. The
results showed negligible effect, indicating midostaurin is unlikely
to have therapeutic potential as a clinical modulator of such
resistance at the dose of 225mg per day.
Our results show no clinical activity of midostaurin in metastatic
melanoma. This schedule did not show pharmacodynamic efficacy
against target PKC isoforms. Other trials with midostaurin as a
single agent have, however, demonstrated biologic and clinical
activity at the same schedule when the patient population was
preselected for expression of midostaurin targets, such as mutated
FLT3 kinase, in AML patients. Demonstrating efficacy and target
modulation in future midostaurin trials may depend on pre-
selecting patients with constitutively activated (phosphorylated)
midostaurin targets: PKC isotypes a, b and g, FLT3, c-kit, KDR,
and PDGF receptor a and b.
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Table 2 Plasma and tissue concentrations of midostaurin and its metabolites CGP62221 and CGP52421 e2 epimer
Plasma concentrations (nM) Tissue concentrations (nM) Tissue/plasma ratios
Subject #
Sampling
day Midostaurin CGP 62221
CGP52421
(e2) Midostaurin
CGP
62221
CGP52421
(e2) Midostaurin
CGP
62221
CGP52421
(e2)
1 28 4649 10132 22448 — — — — — —
3 29 1765 2995 13352 1528 1022 1503 0.87 0.34 0.11
7 29 1437 5761 10767 — — — — — —
8 29 2297 5280 15869 358 651 776 0.16 0.12 0.05
9 30 3549 5265 20340 698 1143 1644 0.20 0.22 0.08
10 28 3212 5586 20944 4246 2353 3212 1.32 0.42 0.15
11 28 2614 4660 19151 58 175 635 0.02 0.04 0.03
12 29
a 1639 3227 16633 607 609 1528 0.37 0.19 0.09
13 30
a 771 2474 11311 266 523 789 0.35 0.21 0.07
14 29
a 2901 7205 18383 579 759 1031 0.20 0.11 0.06
15 27
a 2226 5723 19519 4142 2006 2367 1.86 0.35 0.12
17 29
a 2387 6061 18475 550 661 1569 0.23 0.11 0.08
Mean 2454 5364 17266 1303 990 1505 0.56 0.21 0.085
s.d. 1040 2045 3772 1572 685 796 0.60 0.12 0.036
Median — 2342 5433 18429 593 710 1516 0.29 0.20 0.083
Mimimum — 771 2474 10767 58 175 635 0.02 0.04 0.033
Maximum — 4649 10132 22448 4246 2353 3212 1.86 0.42 0.153
aRepresent blood sampling times only; tumour tissue samples were collected at 2–7 days before or after blood samples.
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